|1.||Colao, Annamaria: 21 articles (06/2015 - 01/2003)|
|2.||Colao, A: 21 articles (03/2015 - 01/2000)|
|3.||Krenning, Eric P: 17 articles (05/2014 - 04/2002)|
|4.||Pivonello, Rosario: 15 articles (04/2011 - 01/2003)|
|5.||Gadelha, Mônica R: 14 articles (12/2015 - 03/2004)|
|6.||Lombardi, Gaetano: 14 articles (04/2011 - 01/2003)|
|7.||Yao, James C: 13 articles (12/2015 - 10/2005)|
|8.||Ferone, D: 13 articles (05/2012 - 04/2000)|
|9.||de Jong, Marion: 12 articles (05/2014 - 01/2003)|
|10.||Reubi, Jean Claude: 12 articles (03/2013 - 05/2002)|
04/01/1989 - "These data suggest that the therapeutic efficacy of octreotide may be related to tumor SRIH receptor levels; the best in vivo responses to octreotide occurred in patients whose tumors contained a high density of homogeneously distributed receptors which had a high affinity for octreotide."
07/01/2009 - "Available evidence indicates that this hybrid imaging technology will become the gold standard for conventional scintigraphy, including bone imaging performed for staging malignancy, and also for the so-called tumor scintigraphies that visualize neoplastic foci via tumor-specific agents such as octreotide labeled with (111)In or (131)I. Another important indication for SPECT/CT is sentinel lymph node scintigraphy, where SPECT/CT fusion helps considerably in localizing the first lymph node draining a tumor. "
02/01/1998 - "No difference in the pretreatment uptake of octreotide by the primary tumor was identified between patients with tumor progression and those with partial or complete remission. "
11/01/1992 - "Two patients whose serum alpha-subunit level did not significantly change while receiving octreotide had a reduction in tumor size or definite improvement in visual field abnormalities. "
06/01/2001 - "In these tumors, octreotide scintigraphy is superior to any other staging method. "
05/01/2009 - "This first randomized study in unselected patients indicates that the 48-week treatment outcome of octreotide LAR as first-line treatment of acromegaly does not significantly differ from surgery. "
08/01/2009 - "High-dose octreotide treatment is safe and effective (normalisation of IGF1 levels) in a subset of patients with active acromegaly inadequately controlled with long-term SSA. "
07/01/2010 - "Critical appraisal of a randomized trial: surgery is superior to octreotide LAR in newly diagnosed patients with acromegaly."
10/01/2000 - "Octreotide LAR proved effective for the treatment of acromegaly and was well tolerated. "
11/01/1995 - "Sandostatin-LAR is an effective and well-tolerated treatment for patients with acromegaly. "
06/01/1995 - "Octreotide is very effective in controlling RRT diarrhea. "
09/01/2007 - "Administration of octreotide was effective in relieving his secretory diarrhea. "
12/01/2006 - "Long-acting octreotide is effective in the treatment of severe diarrhea in patients after pelvic pouch surgery."
06/01/1998 - "The demonstrated safety and efficacy of octreotide in this patient population support further investigation of this therapeutic strategy for GVHD-induced diarrhea. "
06/01/1998 - "In this pilot study, octreotide treatment was effective in reducing the amount of diarrhea in patients with acute GVHD. "
|4.||Carcinoid Tumor (Carcinoid)
08/01/1995 - "Octreotide has proven therapeutically effective in carcinoid syndrome, but the rarity of carcinoid tumors has hampered detailed dose-ranging studies. "
10/01/2008 - "Octreotide has proven to be an effective agent for symptoms of carcinoid syndrome. "
12/01/2000 - "Octreotide was initiated, resulting in marked improvement in carcinoid symptoms. "
01/01/1991 - "Complete remission of the tumour by low-dose (2 x 100 micrograms daily) octreotide was observed in one carcinoid patient. "
06/01/2003 - "Short term and long term therapy with octreotide significantly improves survival and reduces the severity of 'carcinoid crises'. "
07/01/2013 - "We conclude that octreotide treatment in patients with esophageal variceal hemorrhage can result in a significant decrease of dominant power, which correlates with the hemostatic efficacy of octreotide, so the change of dominant power could be used as a predictor of evaluating the treatment efficacy of octreotide in esophageal variceal hemorrhage patients. "
09/01/2002 - "Octreotide appeared to be more effective in controlling acute bleeding in patients with hypertensive gastropathy, with significantly rapid action, smaller transfusion requirements, and minor side-effects. "
10/01/2004 - "These results suggest that octreotide is effective in the treatment of esophageal variceal bleeding and it is a valuable adjuvant treatment in association with endoscopic management."
05/01/1997 - "In randomized controlled trials octreotide has been effective in halting initial hemorrhage and in preventing reoccurrence of bleeding. "
10/01/2004 - "Octreotide was found to be effective regarding hemostasis at 48 hours and on day 7 after the index bleeding episode. "
|1.||Somatostatin (Somatotropin Release-Inhibiting Factor)
|3.||Somatostatin Receptors (Somatostatin Receptor)
|6.||Thyrotropin (Thyroid-Stimulating Hormone)
|8.||Growth Hormone (Somatotropin)
|9.||Insulin-Like Growth Factor I (IGF-1)
|1.||Drug Therapy (Chemotherapy)
|4.||Palliative Care (Palliative Medicine)